natgillin/translations-raw huggingface dataset:
You should inform your doctor if you have recently changed or intend to change your diet substantially (e.g. from normal diet to strict vegetarian diet) or if you are suffering from states of renal tubulary acidosis (RTA, an excess of acid-forming substances in the blood due to renal dysfunction (poor kidney function)) or severe infections of the urinary tract (structure that carries urine) as your doctor may need to adjust the dose of your medicine.
Obvestite svojega zdravnika, če ste pred kratkim spremenili ali če nameravate bistveno spremeniti prehrano (npr. če preidete iz običajne hrane na strogo vegetarijansko prehrano), ali če imate ledvično tubularno acidozo (preveliko količino kislih spojin v krvi zaradi renalne disfunkcije (slabega delovanja ledvic) ali če ste zboleli zaradi hudega vnetja sečil (struktura po kateri se prenaša seč).
What is Memantine Merz used for
Za kaj uporabljamo zdravilo Memantine Merz
Memantine Merz 5 mg film-coated tablets are presented as white to off-white, oval-oblong with imprint ‘5' on one side and imprint ‘MEM' on the other side.
Memantine Merz 5 mg filmsko obložene tablete so bele do belkaste, ovalne in podolgovate z vtisnjeno številko "5" na eni strani in vtisnjeno besedo "MEM" na drugi strani.
Memantine Merz 5 mg film-coated tablets Memantine Merz 10 mg film-coated tablets Memantine Merz 15 mg film-coated tablets Memantine Merz 20 mg film-coated tablets
Memantine Merz 5 mg filmsko obložene tablete Memantine Merz 10 mg filmsko obložene tablete Memantine Merz 15 mg filmsko obložene tablete Memantine Merz 20 mg filmsko obložene tablete
Memantine Merz 10 mg film-coated tablets
Memantine Merz 10 mg filmsko obložene tablete
Talk to your doctor or pharmacist before taking Memantine Merz - if you have a history of epileptic seizures - if you have recently experienced a myocardial infarction (heart attack), or if you are suffering from congestive heart failure or from an uncontrolled hypertension (high blood pressure).
- če ste v preteklosti imeli epileptične napade - če ste pred kratkim preboleli srčni infarkt (srčna kap), imate kongestivno srčno odpoved ali neurejeno hipertenzijo (visok krvni tlak).
Memantine Merz 5 mg film-coated tablets Memantine Merz 10 mg film-coated tablets Memantine Merz 15 mg film-coated tablets Memantine Merz 20 mg film-coated tablets Memantine hydrochloride
Memantine Merz 5 mg filmsko obložene tablete Memantine Merz 10 mg filmsko obložene tablete Memantine Merz 15 mg filmsko obložene tablete Memantine Merz 20 mg filmsko obložene tablete memantinijev klorid
One pump actuation delivers 0.5 ml solution which contains 5 mg of memantine hydrochloride which is equivalent to 4.16 mg memantine.
Ena aktivacija črpalke (en pritisk navzdol) dovede 0,5 ml raztopine, ki vsebuje 5 mg memantinijevega klorida, kar ustreza 4,16 mg memantina.
EXP {MM/YYYY}
Uporabno do: {MM/LLLL}
Week 1 (day 1-7): The patient should take one 5 mg film-coated tablet per day for 7 days.
1. teden (1.-7. dan): Bolnik naj sedem dni jemlje eno 5 mg filmsko obloženo tableto na dan.
Memantine Merz 10 mg 7 film-coated tablets.
Memantine Merz 10 mg 7 filmsko obloženih tablet.
Memantine Merz 20 mg film-coated tablets Memantine hydrochloride
Memantine Merz 20 mg filmsko obložene tablete memantinijev klorid
Titanium dioxide (E 171)
Obloga tablete hipromeloza makrogol 400 titanov dioksid (E 171)
Week 3 (day 15-21): The patient should take one 15 mg film-coated tablet per day for 7 days.
3. teden (15.-21. dan): Bolnik naj sedem dni jemlje eno 15 mg filmsko obloženo tableto na dan.
Each pump actuation delivers 0.5 ml solution which contains 5 mg of memantine hydrochloride which is equivalent to 4.16 mg memantine.
Vsaka aktivacija črpalke (en pritisk navzdol) dovede 0.5 ml raztopine, ki vsebuje 5 mg memantinijevega klorida, kar ustreza 4,16 mg memantina.
FREQUENCY ADVERSE REACTION
Neznana pogostnost
Memantine Merz film-coated tablets are presented as pale yellow to yellow, oval shaped film-coated tablet with breaking line and engravings "1-0" on one side and "M M" on the other side.
Memantine Merz filmsko obložene tablete so bledo rumene do rumene, ovalne, filmsko obložene tablete z razdelilno zarezo in vtisnjeno številko "1 0" na eni strani in besedo "M M" na drugi strani.
Each film-coated tablet contains 20 mg of memantine hydrochloride equivalent to 16.62 mg memantine.
Ena filmsko obložena tableta vsebuje 20 mg memantinijevega klorida, kar ustreza 16,62 mg memantina.
The 10 mg film-coated tablets are pale yellow to yellow, oval shaped film-coated tablet with breaking line and engravings "1-0" on one side and "M M" on the other side The tablet can be divided into equal halves.
10 mg filmsko obložene tablete so bledo rumene do rumene, ovalne, z razdelilno zarezo in vtisnjeno številko "1 0" na eni strani in vtisnjeno besedo "M M" na drugi strani.
Magnesium stearate
Peroralna raztopina.
Pale red to grey-red, oval-oblong film-coated tablets with imprint “20” on one side and imprint “MEM” on the other side.
Bledo rdeče do sivo rdeče, ovalno podolgovate, z vtisnjeno številko "20" na eni strani in vtisnjeno besedo "MEM" na drugi strani.
Memantine Merz 10 mg film-coated tablets are presented as pale yellow to yellow, oval shaped filmcoated tablet with breaking line and engravings "1-0" on one side and "M M" on the other side The tablet can be divided into equal halves.
Memantine Merz 10 mg filmsko obložene tablete so bledo rumene do rumene, ovalne, z razdelilno zarezo in vtisnjeno številko "1 0" na eni strani in vtisnjeno besedo "M M" na drugi strani.
Dyspnoea
Omotica
Memantine Merz 10 mg film-coated tablets Memantine hydrochloride
Memantine Merz 10 mg filmsko obložene tablete memantinijev klorid
No cytochrome P 450 catalysed metabolism has been detected in vitro.
Nobeden od teh metabolitov nima antagonističnega učinka na NMDA. In vitro niso zaznali presnove preko citokroma P 450.
MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS BLISTER FOR TABLETS
PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA PRETISNEM OMOTU ALI DVOJNEM TRAKU
Tablet coating
PRETISNI OMOT ZA TABLETE
Memantine Merz film-coated tablets are presented as pale red to grey-red, oval-oblong film-coated tablets with imprint ‘20' on one side and imprint ‘MEM' on the other side.
Memantine Merz filmsko obložene tablete so bledo rdeče do sivo rdeče, ovalno podolgovate, filmsko obložene tablete z vtisnjeno številko "20" na eni strani in vtisnjeno besedo "MEM" na drugi strani.
Keep out of the sightand reach of children.
Zdravilo shranjujte nedosegljivo otrokom in izven vidnega polja otrok!
Memantine Merz 5 mg/pump actuation, oral solution
Memantine Merz 5 mg/pritisk peroralna raztopina
Colloidal anhydrous silica
nevroleptiki (zdravila za zdravljenje duševnih motenj) peroralni antikoagulanti
Pale yellow to yellow, oval shaped film-coated tablet with breaking line and engravings "1-0" on one side and "M M" on the other side.
Bledo rumene do rumene, ovalne filmsko obložene tablete, z razdelilno zarezo in vtisnjeno številko "1 0" na eni strani in vtisnjeno besedo "M M" na drugi strani.
half a 10 mg tablet week 2
1. teden polovico 10 mg tablete
MARKETING AUTHORISATION NUMBER(S) 13.
ŠTEVILKA (ŠTEVILKE) DOVOLJENJA (DOVOLJENJ) ZA PROMET Z ZDRAVILOM
Memantine Merz 5 mg/pump actuation, oral solution memantine hydrochloride
Memantine Merz 5 mg/pritisk peroralna raztopina memantinijev klorid
PARTICULARS TO APPEAR ON THE OUTER PACKAGING CARTON FOR 42, 50 AND 98 TABLETS AS INTERMEDIATE PACK / COMPONENT OF A MULTIPACK (WITHOUT BLUE BOX)
ŠKATLA ZA 42, 50 IN 98 TABLET KOT PRIMARNA OVOJNINA/DEL VEČKRATNEGA
Week 2 (day 8-14): The patient should take one 10 mg film-coated tablet per day for 7 days.
2. teden (8.-14. dan): Bolnik naj sedem dni jemlje eno 10 mg filmsko obloženo tableto na dan.
- if you are allergic (hypersensitive) to memantine hydrochloride or any of the other ingredients of Memantine Merz oral solution (listed in section 6).
- če ste alergični na (preobčutljivi za) memantinijev klorid ali katerokoli sestavino zdravila
In order to reduce the risk of undesirable effects the maintenance dose is achieved by upward titration of 5 mg per week over the first 3 weeks as follows.
Največji dnevni odmerek je 20 mg. Da bi zmanjšali pojavnost neželenih učinkov, je potrebno postopno zviševanje odmerka po 5 mg na teden v prvih treh tednih zdravljenja, dokler ni dosežen vzdrževalni odmerek, kot je navedeno.
one 10 mg tablet week 3
2. teden ena 10 mg tableta
Memantine Merz should be administered once a day and should be taken at the same time every day.
Zdravilo Memantine Merz je treba dajati enkrat dnevno in ob istem času vsak dan. Tableto lahko bolnik zaužije s hrano ali brez.
one pump actuation.
Enaa aktivacija črpalke (en pritisk navzdol) dovede
The patient should take one 10 mg film-coated tablet per day (pale yellow to yellow, oval shaped) for 7 days.
Bolnik naj 7 dni jemlje eno 15 mg filmsko obloženo tableto na dan (sivo oranžna, ovalna in podolgovata).
In patients with severe renal impairment (creatinine clearance 5 - 29 ml/min) daily dose should be 10 mg (1 ml solution, equivalent to two pump actuations) per day.
5-29 ml/min) naj bo dnevni odmerek 10 mg (1 ml raztopine, kar ustreza dvema pritiskoma navzdol).
10 mg tablet week 3
10 mg tableta
Do not use Memantine Merz after the expiry date which is stated on the carton and the blister after EXP.
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli in na pretisnem omotu poleg oznake EXP. Rok uporabnosti zdravila se izteče na zadnji dan navedenega meseca.
Potassium sorbate Sorbitol E 420
FARMACEVTSKI PODATKI 6.1 Seznam pomožnih snovi kalijev sorbat sorbitol (E 420)
The maximum daily dose is 20 mg per day.
Priporočeni odmerek je 20 mg na dan.
Week 4 (day 22-28): The patient should take one 20 mg film-coated tablet per day (grey-red, oval-oblong) for 7 days.
2. teden (8.-14. dan): Bolnik naj 7 dni jemlje eno 10 mg filmsko obloženo tableto na dan (bledo rumena do rumena, ovalna).
These factors include drastic changes in diet, e.g. from a carnivore to a vegetarian diet, or a massive ingestion of alkalising gastric buffers.
prehod z običajne na vegetarijansko prehrano ali masivno zaužitje alkalno delujočih snovi proti želodčni kislini.
Week 1 (day 1-7): The patient should take one 5 mg film-coated tablet per day (white to off-white, oval-oblong) for 7 days.
Bolnik naj 7 dni jemlje eno 5 mg filmsko obloženo tableto na dan (bela do belkasta, ovalna in podolgovata).
Lot {number} See embossed stamp.
Serija {številka} Glejte odtis na robu.
Tablet core
Glavobol aplikacije
Common
POGOSTNOST
Package leaflet: Information for the user Memantine Merz 20 mg film-coated tablets
NAVODILA ZA UPORABO Memantine Merz 20 mg filmsko obložene tablete memantinijev klorid
The dosing pump head has two positions and is easy to turn - anticlockwise (unlocked position) and clockwise (locked position).
(odklenjen položaj) in v smeri urnega kazalca (zaklenjen položaj).
NN:
Odrasli:
This summary was last updated in 07-2008.
Povzetek je bil nazadnje posodobljen 07-2008.
As the company had supplied the additional information requested, the ‘Exceptional Circumstances' ended on 8 July 2008.
Ker je družba predložila dodatne zahtevane informacije so „izjemne okoliščine“ prenehale veljati 8. julija 2008.
The marketing authorisation was renewed on 27 May 2008.
Dovoljenje za promet je bilo obnovljeno dne 27. maja 2008.
The studies were still ongoing at the time of the medicine's assessment.
Študije so v času ocenjevanja zdravila še potekale.
It contains the active substance enfuvirtide (90 mg/ml).
Vsebuje zdravilno učinkovino enfuvirtid (90 mg/ml).
This prevents the virus from attaching to the surface of human cells and infecting them.
To preprečuje, da bi se virus vezal na površino človeških celic in jih okužil.
On average, the patients had been given an average of 12 antiviral medicines over a seven-year period.
Povprečno so bolniki prejeli 12 protivirusnih zdravil v sedemletnem obdobju.
Fuzeon was originally authorised under ‘Exceptional Circumstances', because for scientific reasons it had not been possible to obtain complete information on the medicine.
Zdravilo Fuzeon je bilo prvotno odobreno v „izjemnih okoliščinah“, ker zaradi znanstvenih razlogov ni bilo mogoče pridobiti vseh informacij o zdravilu Fuzeon.
The European Commission granted a marketing authorisation valid throughout the European Union for Fuzeon to Roche Registration Limited on 27 May 2003.
Evropska komisija je dovoljenje za promet z zdravilom Fuzeon, veljavno po vsej Evropski uniji, odobrila družbi Roche Registration Limited dne 27. maja 2003.
Other information about Fuzeon:
Druge informacije o zdravilu Fuzeon:
Fuzeon has also been studied in 39 children aged between three and 16 years.
Zdravilo Fuzeon so preučevali tudi pri 39 otrocih, starih med tri in 16 let.
The dose for children aged six to 16 years depends on body weight.
Odmerek za otroke, stare med šest in 16 let, je odvisen od telesne mase.
The main measure of effectiveness was the change in the levels of HIV in the blood (viral load) after 48 weeks of treatment.
Glavno merilo učinkovitosti je bila sprememba koncentracije virusa HIV v krvi (virusnega bremena) po 48 tednih zdravljenja.
In clinical studies, injection site reactions have been reported in 98% of patients, mostly occurring within the first week of treatment.
V kliničnih študijah so o reakcijah na mestu injiciranja poročali pri 98 % bolnikih, pretežno v prvem tednu zdravljenja.
It caused mild to moderate pain or discomfort, which did not increase during treatment.
Povezane so bile z blago do zmerno bolečino ali neugodjem, ki se med zdravljenjem ni povečalo.
EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) FUZEON EPAR summary for the public
EVROPSKO JAVNO POROČILO O OCENI ZDRAVILA (EPAR) FUZEON Povzetek EPAR za javnost
What benefit has Fuzeon shown during the studies?
Kakšne koristi je zdravilo Fuzeon izkazalo med študijami?
The Committee recommended that Fuzeon be given marketing authorisation.
Odbor je priporočil, da se za zdravilo Fuzeon odobri dovoljenje za promet.
The values in the second study were 96 and 78%, respectively.
V drugi študiji so bile vrednosti za prvo skupino bolnikov 96 %, za drugo pa 78 %.
What is the risk associated with Fuzeon?
Kakšna tveganja so povezana z zdravilom Fuzeon?
It is for use in patients who have stopped responding to, or cannot take, other antiviral medicines.
Namenjeno je uporabi pri bolnikih, ki so se nehali odzivati na druga protivirusna zdravila ali jih ne smejo jemati.
Fuzeon should be prescribed by a doctor who has experience in the treatment of HIV infection.
Zdravilo Fuzeon mora predpisati zdravnik, ki ima izkušnje z zdravljenjem okužb s HIV.
The two main studies of Fuzeon included 1,013 patients aged 16 years or over who were infected with HIV and had taken, or were not responding to, other antiviral medicines.
V dve glavni študiji zdravila Fuzeon je bilo vključenih 1013 bolnikov, starih 16 let ali več, ki so bili okuženi s HIV in so jemali druga protivirusna zdravila ali se nanje niso odzivali.
Fuzeon does not cure HIV infection or AIDS, but it may delay the damage to the immune system and the development of infections and diseases associated with AIDS.
Zdravilo Fuzeon ne ozdravi okužbe s HIV ali AIDS-a, vendar pa lahko upočasni slabšanje imunskega sistema ter razvoj okužb in bolezni, povezanih z AIDS-om.
Fuzeon binds to a protein on the surface of HIV.
Zdravilo Fuzeon se veže na beljakovino na površini virusa HIV.
Doctors should only prescribe Fuzeon once they have looked at the antiviral medicines the patient has taken before and the likelihood that the virus will respond to the medicine.
Zdravniki smejo predpisati zdravilo Fuzeon šele potem, ko se seznanijo s protivirusnimi zdravili, ki jih je bolnik jemal prej, in verjetnostjo, da se bo virus odzval na zdravilo.
In the first study, viral loads fell by an average of 98% in the patients taking Fuzeon, compared with 83% in the patients not taking Fuzeon.
V prvi študiji se je pri bolnikih, ki so jemali zdravilo Fuzeon, virusno breme zmanjšalo za povprečno 98 % v primerjavi s 83 % pri bolnikih, ki niso jemali zdravila Fuzeon.
The approved dose of Fuzeon in children brings about similar levels of the active substance in the blood to the approved dose in adults.
Odobreni odmerek zdravila Fuzeon za otroke zagotavlja približno enako koncentracijo zdravilne učinkovine v krvi kot odobreni odmerek pri odraslih.
Fuzeon should not be used in people who may be hypersensitive (allergic) to enfuvirtide or any of the other ingredients.
Zdravila Fuzeon ne smejo uporabljati osebe, ki utegnejo biti preobčutljive za (alergične na) enfuvirtid ali katero koli drugo sestavino zdravila.
Fuzeon is not recommended for use in children under six years of age.
Uporaba zdravila Fuzeon pri otrocih, mlajših od šest let, ni priporočljiva.
As HIV can only reproduce itself within cells, Fuzeon, taken in combination with other antiviral medicines, reduces the level of HIV in the blood and keeps it at a low level.
Ker se lahko virus HIV razmnožuje samo v celicah, zdravilo Fuzeon, če ga jemljemo v kombinaciji z drugimi protivirusnimi zdravili, zmanjša koncentracijo virusa HIV v krvi in jo ohranja na nizki ravni.
It is used in combination with other antiviral medicines for the treatment of patients infected with human immunodeficiency virus type 1 (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS).
Uporablja se v kombinaciji z drugimi protivirusnimi zdravili za zdravljenje bolnikov, okuženih z virusom humane imunske pomanjkljivosti tipa 1 (HIV-1), tj. virusom, ki povzroča sindrom pridobljene imunske pomanjkljivosti (AIDS).
In adults, it is given as one 90-mg injection twice a day, injected under the skin of the upper arm, upper thigh or abdomen (tummy).
Pri odraslih se daje v obliki ene 90-miligramske injekcije dvakrat na dan, injicirane pod kožo nadlakti, zgornjega dela stegna ali trebuha.
Fuzeon is an antiviral medicine.
Zdravilo Fuzeon je protivirusno zdravilo.
The most common side effects with Fuzeon (seen in more than 1 patient in 10) are injection site reactions (pain and inflammation at the site of injection), peripheral neuropathy (damage to the nerves in the extremities causing tingling or numbness in the hands and feet) and weight loss.
Najpogostejši neželeni učinki zdravila Fuzeon (opaženi pri več kot 1 bolniku od 10) so reakcije na mestu injiciranja (bolečina in vnetje na mestu injiciranja), periferna nevropatija (poškodba živcev v okončinah, ki povzroči mravljinčenje ali odrevenelost rok in nog) ter izguba telesne mase.
Both studies compared the effects of Fuzeon, in combination with ‘optimised background therapy' (a combination of other antiviral medicines chosen for each patient as they had the best chances of reducing the levels of HIV in the blood), compared with optimised background therapy without Fuzeon.
V obeh študijah so učinke zdravila Fuzeon v kombinaciji z „optimiziranim osnovnim zdravljenjem“ (kombinacijo drugih protivirusnih zdravil, izbranih za posameznega bolnika, ki je obetala največjo verjetnost za zmanjšanje koncentracije virusa HIV v krvi) primerjali z optimiziranim osnovnim zdravljenjem brez zdravila Fuzeon.
The site of injection must be changed for each injection.
Za vsako injekcijo je treba izbrati drugo mesto injiciranja.
As with all other anti-HIV medicines, patients taking Fuzeon may be at risk of osteonecrosis (death of bone tissue) or immune reactivation syndrome (symptoms of infection caused by the recovering immune system).
Enako kot pri drugih zdravilih proti virusu HIV obstaja pri bolnikih, ki jemljejo zdravilo Fuzeon, tveganje za osteonekrozo (odmiranje kostnega tkiva) ali sindrom imunske reaktivacije (simptome okužbe, ki jo povzroči imunski sistem med okrevanjem).
Why has Fuzeon been approved?
Zakaj je bilo zdravilo Fuzeon odobreno?
Patients who have problems with their liver may be at an elevated risk of liver damage when taking treatment for HIV infection.
Pri bolnikih, ki imajo težave z jetri, obstaja pri jemanju zdravila proti okužbi s HIV povečano tveganje za poškodbe jeter.
Taking Fuzeon with optimised background therapy was more effective at reducing viral loads than optimised background therapy alone.
Jemanje zdravila Fuzeon z optimiziranim osnovnim zdravljenjem je bilo pri zmanjševanju virusnega bremena učinkovitejše od samostojnega optimiziranega osnovnega zdravljenja.
For the full list of all side effects reported with Fuzeon, see the Package Leaflet.
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Fuzeon, glejte navodilo za uporabo.
The Committee for Medicinal Products for Human Use (CHMP) decided that Fuzeon's benefits are greater than its risks in combination with other antiretroviral medicinal products for the treatment of HIV-1 infected patients who have received treatment with and failed on regimens containing at least one medicinal product from each of the following classes, protease inhibitors, non-nucleoside reverse transcriptase inhibitors and nucleoside reverse transcriptase inhibitors, or who have intolerance to previous antiretroviral regimens.
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila Fuzeon v kombinaciji z drugimi protiretrovirusnimi zdravili za zdravljenje bolnikov, okuženih s HIV-1 in neuspešno zdravljenih z režimi zdravljenja, ki so vsebovali vsaj eno od zdravil iz vsakega od naslednjih razredov: zaviralci proteaz, nenukleozidni zaviralci reverzne transkriptaze in nukleozidni zaviralci reverzne transkriptaze, ali bolnikov, ki prejšnjih protiretrovirusnih režimov zdravljenja ne prenašajo, večje od z njim povezanih tveganj.
These must include at least one medicine from each of the following classes of medicine used to treat HIV infection: protease inhibitors; non-nucleoside reverse transcriptase inhibitors; and nucleoside reverse transcriptase inhibitors.
Med temi mora biti vsaj eno zdravilo iz vsakega od naslednjih razredov zdravil, ki se uporabljajo za zdravljenje okužb s HIV: zaviralci proteaze, nenukleozidni zaviralci reverzne transkriptaze in nukleozidni zaviralci reverzne transkriptaze.
The active substance in Fuzeon, enfuvirtide, is a fusion inhibitor.
Zdravilna učinkovina zdravila Fuzeon, enfuvirtid, je zaviralec zlitja.
Fuzeon can be injected by the patient or by a carer, provided that the person giving the injection follows the detailed instructions given in the Package Leaflet.
Zdravilo Fuzeon si lahko injicira bolnik sam ali mu ga injicira negovalec, če oseba, ki daje injekcijo, natančno upošteva napotke v navodilu za uporabo.
Fuzeon is a powder that is made up into a solution for injection.
Zdravilo Fuzeon je prašek za pripravo raztopine za injiciranje.
What is Fuzeon used for?
Za kaj se zdravilo Fuzeon uporablja?
How has Fuzeon been studied?
Kako je bilo zdravilo Fuzeon raziskano?
How does Fuzeon work?
Kako zdravilo Fuzeon deluje?
The full EPAR for Fuzeon can be found here.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Fuzeon je na voljo tukaj.
What is Fuzeon?
Kaj je zdravilo Fuzeon?
How is Fuzeon used?
Kako se zdravilo Fuzeon uporablja?
Pharmaceutical Form Route of Administration Packaging
Številka EU Izmišljeno ime jakost farmacevtska oblika pot uporabe ovojnina vsebina (koncentracija) velikost pakiranja
1 vial + 1 vial
1 viale + 1 viale
2 vials + 2 vials
2 vial + 2 vial
Strength Pharmaceutical Form Route of Administration
Izmišljeno ime jakost farmacevtska oblika pot uporabe ovojnina vsebina velikost pakiranja
You will also need:
Potrebovali boste tudi:
This should be done right after step J.
To morate storiti takoj po koraku J.
Always wash your hands and ensure that the area around you is clean.
Vedno si umijte roke in poskrbite, da je okolica okrog vas čista.
b Calculation based on 67 profiles.
b Osnova izračuna je 67 profilov.
The package contains:
Pakiranje vsebuje:
You can do this by holding them in your hands until they feel as warm as your hands, see figure A.
To lahko storite tako, da ju držite v dlaneh, dokler ne postaneta enako topli kot vaše dlani (glejte sliko A).
From a microbiological point of view, the product should be used immediately.
Z mikrobiološkega stališča je treba zdravilo uporabiti takoj.
Always use an aseptic technique.
Vedno uporabljajte aseptičen postopek.